Stocks Health care CRSP
NASDAQ · Health careCRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG brought in $13.4M of revenue over the twelve months to June 30, 2026, down 64.8% from a year earlier. It posted a net loss of $451.1M. In fiscal 2025 capital spending exceeded operating cash flow by $345.9M. At June 30, 2026 it held $291.3M in cash against $586.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What CRISPR Therapeutics AG does
CRISPR Therapeutics AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRSP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.5M | -$581.6M | -$6.47 | -$345.9M |
| 2024 | $37.3M | -$366.3M | -$4.34 | -$144.7M |
| 2023 | $371.2M | -$153.6M | -$1.94 | -$269.8M |
| 2022 | $1.2M | -$650.2M | -$8.36 | -$532.9M |
| 2021 | $915M | $377.7M | $4.70 | $457.3M |
| 2020 | $719K | -$348.9M | -$5.29 | -$256.7M |
Latest SEC filings
What CRISPR Therapeutics AG has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 5, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026
- May 4, 2026
Questions about CRSP
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CRSP.
Is CRISPR Therapeutics AG profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $451.1M on revenue of $13.4M.
How much revenue does CRISPR Therapeutics AG make?
Over the twelve months to June 30, 2026 CRISPR Therapeutics AG reported revenue of $13.4M. That is 64.8% less than a year earlier.
When did CRISPR Therapeutics AG last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Follow CRSP
Get an email when CRISPR Therapeutics AG files with the SEC: results, executive changes, material agreements and annual reports.
Follow CRSP: get an email when it filesWhere the numbers come from
Financial figures are the values CRISPR Therapeutics AG tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.